REG - e-Therapeutics plc - Filing of four patent applications

E-TherapeuticsAnnouncement

07/02/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230207:nRSG0686Pa&default-theme=true

RNS Number : 0686P  e-Therapeutics plc  07 February 2023

 

e-therapeutics plc

("e-therapeutics" or the "Company")

 

Filing of four new patent applications on novel target innovation and

new siRNA chemistries

 

 

London, UK, 07 February 2023- e-therapeutics plc (AIM: ETX; OTCQX;
ETXPF), a company integrating computational power and biological data to
discover life-transforming RNAi medicines, announces the filing of four new
patent applications to protect innovation around novel gene targets,
associated disease relevant biology as well as proprietary siRNA ('short
interfering RNA') stabilisation chemistries.

 

The four new patent applications add to a rapidly growing patent portfolio
reflecting the Company's continued intense rate of innovation associated with
developing a computationally driven in-house pipeline of RNAi drug candidates
across a range of therapeutic areas. The new patent applications build on
an active period of IP generation reported in 2022 where a series of patent
applications were filed to protect 13 inventions.

 

Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented:

 

"This latest announcement of patent filings reflects our continued pace of
innovation and progress towards an in-house pipeline of first-in-class RNAi
candidates derived from our computational platform. We will continue to build
on this progress, maintain the momentum of invention and actively protect our
expanding intellectual property portfolio."

 

 

 

Enquiries:

 

 e-therapeutics plc
 Ali Mortazavi,                                                                        Tel: +44 (0)20 4551 8888
 CEO

                                                                                     www.etherapeutics.co.uk
 James Chandler, VP IR & Communications

      SP Angel Corporate Finance LLP                                                   Tel: +44(0)20 3470 0470
 Nominated Adviser and Broker
 Matthew Johnson/Harry Davies-Ball (Corporate Finance)
 Vadim Alexandre/Rob Rees (Corporate Broking)

 

 

About e-therapeutics plc www.etherapeutics.co.uk
(http://www.etherapeutics.co.uk)

 

e-therapeutics plc ("ETX") integrates computational power and biology
information to discover life-transforming RNAi medicines.  The Company's
technology uses computation to capture and model human biology, identify
novel targets, and develop RNAi medicines against those targets that can be
rapidly progressed to the clinic.

 

ETX's proprietary Computational Biology Platform enables the generation and
analysis of biological network models, providing a novel and mechanistic
approach to drug discovery that explicitly considers the true complexity of
biology and makes more reliable predictions from large complex data sets and
ETX's proprietary hepatocyte knowledgebase - the world's most comprehensive
and integrated hepatocyte-centric data and information resource.  The Company
generates, prioritises and tests millions of hypotheses in silico to identify
better therapeutic targets with higher confidence.

 

ETX's proprietary RNAi Platform enables the targeted delivery to hepatocytes
in the liver and the specific silencing of novel disease-associated genes,
identified by ETX's Computational Biology Platform.  The focus on hepatocytes
offers the opportunity to work across a wide variety of diseases.  The liver
is a highly metabolically active organ which performs a key role in many
biological processes and vital functions crucial for human health.
ETX's GalNAc-siRNA constructs have demonstrated compelling in vivo
performance in terms of depth of gene silencing and duration of action.

 

ETX is progressing a pipeline of first-in-class pre-clinical RNAi candidates
in several therapeutic areas including haematology, cardiovascular disease
and non-alcoholic steatohepatitis ("NASH").  ETX has also partnered with
biopharma companies such as Novo Nordisk, Galapagos NV and iTeos
Therapeutics using its computational network biology approach across a
diverse range of drug discovery projects.

 

The Company is based in London, UK and listed on the Alternative Investment
Market of the London Stock Exchange ("AIM"), with ticker symbol ETX.
e-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United
States, under ticker symbol ETXPF.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCNKABQPBKDKBK